Document is current

Article History

Received: 24 July 2025

Revised: 19 November 2025

Accepted: 21 November 2025

First Online: 3 December 2025

Declarations

:

: AS: Chugai (honoraria); YN: Chugai (research funding); SO: Novartis, Takeda, AstraZeneca, AbbVie, PharmaEssensia, Bristol Myers Squibb, Janssen, Amgen, Sanofi (honoraria); RS: Chugai, Kyowa Kirin, Shionogi, Taiho, Eisai, Meiji Seika, Otsuka (research funding); Chugai, Kyowa-Kirin, AbbVie, Bristol Myers Squibb, Eisai, Otsuka, Nihon Shinyaku, Janssen, Takeda, Meiji Seika, Novartis, SymBio, Astellas (honoraria); TMi: Janssen, Chugai, AstraZeneca, Nippon Shinyaku, Sanofi, AbbVie, Bristol Myers Squibb (honoraria); HG: Chugai (research funding); Chugai, Novartis, Bristol Myers Squibb, MSD, Takeda, AbbVie, Gilead, Kyowa-Kirin, GenMab, Sanofi (honoraria); NF: Abbvie, Chugai, Chordia Therapeytics, GenMab, Haihe Biopharma, Incyte, Kyowa Kirin, Loxo Oncology, Ono Pharmaceuticals, Takeda (research funding); editor of the International Journal of Hematology; MS-Y: Chugai, JMS, Asahi Kasei Pharma, Terumo Corporation, Nippon Kayaku, Abbott Medical Japan, Eisai Co, Bristol-Myers Squibb, MSD, Cancer Research Promotion Foundation, Kobayashi Foundation, Takeda Science Foundation, Uehara Memorial Life Science Foundation, Chemical and Serum Therapeutic Research Institute, Takahashi Industrial and Economic Research Foundation (research funding); KI: MSD, AstraZeneca, Abbvie, Incyte, Bristol Myers Squibb, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Daiichi Sankyo, Chugai, Beigene, Genmab, Loxo Oncology, Otsuka, Regeneron, Gilead (other); MSD, AstraZeneca, Abbvie, Incyte, Bristol Myers Squibb, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Daiichi Sankyo, Chugai, Beigene, Genmab, Loxo Oncology, Otsuka, Regeneron, Gilead, Nihon Shinyaku (consulting fees); MSD, AstraZeneca, Abbvie, Bristol Myers Squibb, Novartis, Yakult, Kyowa Kirin, Chugai, Beigene, Genmab, Otsuka, Ono Pharma, Mitsubishi Tanabe Pharmaceutical, Eisai, Symbio Pharmaceuticals, Takeda, Zenyakua, Carna Biosciences, Nihon Shinyaku (honoraria); MN: SymBio Pharmaceuticals (research funding); Chugai, Genmab, (honoraria); HS: AstraZeneca, Ono Pharmaceutical, Chugai, Nippon-Shinyaku, Meiji Seika (honoraria); Chugai, Fujimoto (advisory role); editor of the International Journal of Hematology; TK: Janssen, Ono Pharmaceutical, AstraZeneca, AbbVie, GenMab, BeiGene (honoraria); DE: Nippon Shinyaku, Chugai, Eisai Pharmaceutical InSight (research funding); Eisai, Kyowa Kirin Pharmaceutical, Chugai, AbbVie, Bristol Myers Squibb, Nippon Shinyaku, Ono Pharmaceutical, GenMab, (honoraria); NI: Chugai Pharmaceutical Co., Ltd (current employment); Chugai Pharmaceutical Co., Ltd, Takeda Pharmaceutical (stock or stock options); IM: Chugai, Kyowa Kirin, Esai, AbbVie, Asahi Kasei Pharma, Sumitomo Pharma, Taiho Pharmaceutical, Otsuka (other); Otsuka (consulting fees); Chugai, Novartis, Pfizer Japan, AbbVie, Ono Pharmaceuticals, Sanofi, AstraZeneca, Bristol Myers Squibb, Janssen, Otsuka, Takeda, SymBio Pharmaceuticals, Astellas Pharma (honoraria); KA: LSI, Kyowa Kirin, Sumitomo Pharma, AbbVie (research funding); Kyowa Kirin, Nippon Shinyaku (consulting fees); Asahi Kasei Pharma, Astellas, AstraZeneca, AbbVie, Kyowa Kirin, Chugai, Bristol Myers Squibb, Janssen (honoraria); KK: Chugai, Janssen, Meiji Seika, Novartis, AbbVie, Genmab, Bristol Myers Squibb, Gilead Sciences, Eisai, Astellas Pharma, Otsuka, Kyowa Kirin, Nippon Shinyaku, MSD, Japan Blood Products Organization (honoraria); KM, YF, TMu, SR, HT and TS report no conflicts of interest.

: All patients provided written informed consent for participation in the study. Patients were able to withdraw from the study at any time.

: N/A